论文部分内容阅读
为了探索重组ＩＬ６－ＰＥ４０融合蛋白靶向杀伤白血病的效应，我们已成功地将编码人ＩＬ６Ｒ的全长ｃＤＮＡ转入ＢＮＭＬ大鼠急性早幼粒细胞白血病ＬＴ１２细胞中。本文研究了ＩＬ６ＲｃＤＮＡ转入ＬＴ１２细胞后对该细胞原有生物学特性的影响。结果表明：①ＬＴ１２－ＩＬ６Ｒ￣＋细胞与原代细胞五种酶学组化无任何区别；②ＬＴ１２－ＩＬ６Ｒ￣＋细胞不仅高表达ＩＬ６Ｒ而且仍保持原有的表面抗原性质，如与ＲＭ－１２４单抗结合；③在白血病细胞体内外克隆源试验中，两种细胞系等同；④更重要的是ＬＴ１２－ＩＬ６Ｒ￣＋细胞的致瘤特性无异于ＬＴ１２原代细胞。证明ＬＴ１２－ＩＬ６Ｒ￣＋仍为急性早幼粒细胞白血病。
To explore the effect of recombinant IL6-PE40 fusion targeting leukemia, we have successfully transferred the full-length cDNA encoding human IL6R into BNML rat acute promyelocytic leukemia LT12 cells. This article studies the IL6RcDNA into LT12 cells after the original biological characteristics of the cell. The results showed that: ①LT12-IL6R ~ + cells had no difference from the five kinds of enzymatic histochemistry of primary cells; ②LT12-IL6R ~ + cells not only highly expressed IL6R but also maintained the original surface antigenic properties, ; ③ In the in vitro and in vivo clonogenic assay of leukemia cells, the two cell lines are identical; ④ More importantly, the tumorigenic characteristics of LT12-IL6R ~ + cells are no different from those of LT12 primary cells. Proved that LT12-IL6R ~ + is still acute promyelocytic leukemia.